Celcuity, Inc. (CELC)

Last Closing Price: 138.23 (2026-05-22)

Company Description

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-177.04M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 128.71
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -244.61%
Return on Assets (Trailing 12 Months) -50.22%
Current Ratio (Most Recent Fiscal Quarter) 12.31
Quick Ratio (Most Recent Fiscal Quarter) 12.31
Debt to Common Equity (Most Recent Fiscal Quarter) 6.04
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $1.10
Earnings per Share (Most Recent Fiscal Quarter) $-0.97
Earnings per Share (Most Recent Fiscal Year) $-3.79
Diluted Earnings per Share (Trailing 12 Months) $-3.90
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 48.77M
Free Float 42.27M
Market Capitalization $6.95B
Average Volume (Last 20 Days) 1.26M
Beta (Past 60 Months) 0.09
Percentage Held By Insiders (Latest Annual Proxy Report) 13.33%
Percentage Held By Institutions (Latest 13F Reports) 63.33%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%